| Product Unit Size | Cost | Quantity | Stock |
|---|
Tenofovir is an antiviral compound that is clinically used to treat hepatitis B and HIV-1 infections. Tenofovir is a nucleotide analog and inhibitor of reverse transcriptase. This compound is also in development as a potential treatment for feline leukemia virus (FeLuk).
| Cas No. | 206184-49-8 |
|---|---|
| Purity | ≥98% |
| Formula | C9H14N5O4P • H2O |
| Formula Wt. | 305.23 |
| Chemical Name | [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid;hydrate |
| IUPAC Name | [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid;hydrate |
| Synonym | Tenofovir hydrate |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Qiu LP, Chen L, Chen KP. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Fundam Clin Pharmacol. 2013 Oct 4. [Epub ahead of print]. PMID: 24118072.
Iyidogan P, Anderson KS. Recent findings on the mechanisms involved in tenofovir resistance. Antivir Chem Chemother. 2013 Jun 6. [Epub ahead of print]. PMID: 23744599.
Greggs WM 3rd, Clouser CL, Patterson SE, et al. Discovery of drugs that possess activity against feline leukemia virus. J Gen Virol. 2012 Apr;93(Pt 4):900-5. PMID: 22258856.
Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010 Feb 19;5(2):e9310. PMID: 20174579.